首页 > 最新文献

Therapeutic Apheresis and Dialysis最新文献

英文 中文
The effect of video-based fistula care education on hemodialysis patients' self-care behaviors: A randomized controlled study. 基于视频的瘘管病护理教育对血液透析患者自我护理行为的影响:一项随机对照研究。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-27 DOI: 10.1111/1744-9987.14058
Seda Şahan, Ayşegül Yıldız, Cevriye Özdemir, Elif Günay İsmailoğlu

Objective: This study aimed to determine the effect of face-to-face and video-based education for fistula care on hemodialysis patients' self-care behaviors.

Methods: The study was conducted as a randomized controlled experimental study. Accordingly, 60 patients were included in the study for 95% strength. Fistula care training was given to the patients in the control group using face-to-face education technique. Fistula care training was given to the patients in the experimental group using a video-based technique.

Results: The analysis showed that the post-test second week (p = 0.044) and fourth week (p = 0.00) mean scores of the experimental group were higher compared to those of the control group.

Conclusion: These results showed that the video-based education given to hemodialysis patients was more memorable and instructive than the verbal education, and it was observed that the video-based education showed a higher level of success in developing self-care skills.

目的:本研究旨在确定瘘管病护理面对面和视频教育对血液透析患者自我护理行为的影响。方法:本研究采用随机对照实验研究。因此,60名患者被纳入研究,强度为95%。对照组采用面对面教育技术对患者进行瘘管护理培训。实验组采用视频技术对患者进行瘘管护理培训。结果:分析表明,试验后第2周(p = 0.044)和第四周(p = 0.00)平均得分高于对照组。结论:这些结果表明,对血液透析患者进行的基于视频的教育比口头教育更令人难忘和更有指导性,并且观察到,基于视频的教学在培养自我护理技能方面表现出更高的成功水平。
{"title":"The effect of video-based fistula care education on hemodialysis patients' self-care behaviors: A randomized controlled study.","authors":"Seda Şahan,&nbsp;Ayşegül Yıldız,&nbsp;Cevriye Özdemir,&nbsp;Elif Günay İsmailoğlu","doi":"10.1111/1744-9987.14058","DOIUrl":"10.1111/1744-9987.14058","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to determine the effect of face-to-face and video-based education for fistula care on hemodialysis patients' self-care behaviors.</p><p><strong>Methods: </strong>The study was conducted as a randomized controlled experimental study. Accordingly, 60 patients were included in the study for 95% strength. Fistula care training was given to the patients in the control group using face-to-face education technique. Fistula care training was given to the patients in the experimental group using a video-based technique.</p><p><strong>Results: </strong>The analysis showed that the post-test second week (p = 0.044) and fourth week (p = 0.00) mean scores of the experimental group were higher compared to those of the control group.</p><p><strong>Conclusion: </strong>These results showed that the video-based education given to hemodialysis patients was more memorable and instructive than the verbal education, and it was observed that the video-based education showed a higher level of success in developing self-care skills.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10439690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Water quality and adverse health effects on the hemodialysis patients: An overview. 血液透析患者的水质和不良健康影响:综述。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-06-28 DOI: 10.1111/1744-9987.14032
Raquel Raimundo, Laura Preciado, Rita Belchior, Cristina M M Almeida

Hemodialysis is considered a treatment of choice for patients with renal failure worldwide, allowing the replacement of some kidney functions by diffusion and ultrafiltration processes. Over 4 million people require some form of renal replacement therapy, with hemodialysis being the most common. During the procedure, contaminants in the water and the resulting dialysate may pass into the patient's blood and lead to toxicity. Thus, the quality of the associated dialysis solutions is a critical issue. Accordingly, the discussion of the importance of a dialysis water delivery system controlled by current standards and recommendations, with efficient monitoring methods, disinfection systems, and chemical and microbiological analysis, is crucial for improving the health outcomes of these patients. The importance of treatment, monitoring, and regulation is emphasized by presenting several case studies concerning the contamination of hemodialysis water and the adverse effects on the respective patients.

血液透析被认为是全世界肾功能衰竭患者的首选治疗方法,可以通过扩散和超滤过程替代一些肾功能。超过400万人需要某种形式的肾脏替代治疗,其中血液透析是最常见的。在手术过程中,水中的污染物和由此产生的透析液可能会进入患者的血液并导致毒性。因此,相关透析溶液的质量是一个关键问题。因此,讨论由现行标准和建议控制的透析水输送系统的重要性,以及有效的监测方法、消毒系统以及化学和微生物分析,对于改善这些患者的健康结果至关重要。通过介绍几个关于血液透析水污染和对相应患者的不良影响的案例研究,强调了治疗、监测和调节的重要性。
{"title":"Water quality and adverse health effects on the hemodialysis patients: An overview.","authors":"Raquel Raimundo,&nbsp;Laura Preciado,&nbsp;Rita Belchior,&nbsp;Cristina M M Almeida","doi":"10.1111/1744-9987.14032","DOIUrl":"10.1111/1744-9987.14032","url":null,"abstract":"<p><p>Hemodialysis is considered a treatment of choice for patients with renal failure worldwide, allowing the replacement of some kidney functions by diffusion and ultrafiltration processes. Over 4 million people require some form of renal replacement therapy, with hemodialysis being the most common. During the procedure, contaminants in the water and the resulting dialysate may pass into the patient's blood and lead to toxicity. Thus, the quality of the associated dialysis solutions is a critical issue. Accordingly, the discussion of the importance of a dialysis water delivery system controlled by current standards and recommendations, with efficient monitoring methods, disinfection systems, and chemical and microbiological analysis, is crucial for improving the health outcomes of these patients. The importance of treatment, monitoring, and regulation is emphasized by presenting several case studies concerning the contamination of hemodialysis water and the adverse effects on the respective patients.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9693291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel and highly reliable leak check tests for drop- and external pressure-type cell-free and concentrated ascites reinfusion therapy. 适用于滴注和外压型无细胞和浓缩腹水回输治疗的新型和高度可靠的渗漏检查测试。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-18 DOI: 10.1111/1744-9987.14048
Yasuko Kobayashi, Nana Ozawa, Tamami Yoshida, Takashi Minowa, Yuki Michinaga, Keita Inui, Koji Hashimoto, Yuji Kamijo

Introduction: For safe management of cell-free and concentrated ascites reinfusion therapy (CART), a highly reliable leak test for detecting ascites filter damage is essential. However, such a test has not been established for drop-type CART.

Methods: We devised two novel leak tests for drop- and external pressure-type CART, manual or pump pressurization methods, using high-pressure loading and pressure monitoring, and investigated their reliability.

Results: Both methods could easily load and maintain sufficiently high pressure (>400 Torr) on the hollow fibers for 2 min. No result deviation was noted between different operators. The pressure drops in both methods were identical and significantly lower than those in the leak test using a special CART machine, the e-CART.

Conclusion: The reliability of our revised leak test is equivalent to that of the automatic leak test of e-CART. These highly reliable leak tests may contribute to safety in patients undergoing drop- and external pressure-type CART.

引言:为了安全管理无细胞和浓缩腹水回输治疗(CART),一种高度可靠的检测腹水过滤器损伤的渗漏测试至关重要。然而,还没有为跌落型CART建立这样的测试。方法:我们设计了两种新的跌落型和外压型CART泄漏测试,即手动或泵加压方法,使用高压加载和压力监测,并研究了它们的可靠性。结果:两种方法都可以很容易地加载并保持足够高的压力(>400 Torr)在中空纤维上 min.不同操作人员之间未发现结果偏差。两种方法的压降完全相同,并且明显低于使用特殊CART机器e-CART进行的泄漏测试。结论:我们改进的泄漏测试的可靠性与e-CART的自动泄漏测试相当。这些高度可靠的泄漏测试可能有助于接受降压和外压型CART的患者的安全性。
{"title":"Novel and highly reliable leak check tests for drop- and external pressure-type cell-free and concentrated ascites reinfusion therapy.","authors":"Yasuko Kobayashi,&nbsp;Nana Ozawa,&nbsp;Tamami Yoshida,&nbsp;Takashi Minowa,&nbsp;Yuki Michinaga,&nbsp;Keita Inui,&nbsp;Koji Hashimoto,&nbsp;Yuji Kamijo","doi":"10.1111/1744-9987.14048","DOIUrl":"10.1111/1744-9987.14048","url":null,"abstract":"<p><strong>Introduction: </strong>For safe management of cell-free and concentrated ascites reinfusion therapy (CART), a highly reliable leak test for detecting ascites filter damage is essential. However, such a test has not been established for drop-type CART.</p><p><strong>Methods: </strong>We devised two novel leak tests for drop- and external pressure-type CART, manual or pump pressurization methods, using high-pressure loading and pressure monitoring, and investigated their reliability.</p><p><strong>Results: </strong>Both methods could easily load and maintain sufficiently high pressure (>400 Torr) on the hollow fibers for 2 min. No result deviation was noted between different operators. The pressure drops in both methods were identical and significantly lower than those in the leak test using a special CART machine, the e-CART.</p><p><strong>Conclusion: </strong>The reliability of our revised leak test is equivalent to that of the automatic leak test of e-CART. These highly reliable leak tests may contribute to safety in patients undergoing drop- and external pressure-type CART.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10021308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rescue plan for CAPD peritonitis: Using ultrasonography as a guide on when to remove the catheter. CAPD腹膜炎的抢救计划:使用超声波作为何时移除导管的指南。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-26 DOI: 10.1111/1744-9987.14042
Dusit Lumlertgul, Nantawan Tinroongroj, Suthaporn Lumlertgul, Pannamart Siwapitak, Rattanaluck Tungkanakorn, Supaporn Kaewpanya

Introduction: Ultrasound has been found to facilitate early identification of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).

Methods: A retrospective analysis was carried out to evaluate the effectiveness of ultrasonography-guided removal of the Tenckhoff catheter in reducing complications like a shift to hemodialysis or death in CAPD patients.

Results: The "peritonitis rescue plan" supported timely decision-making for the removal of the infected catheter and resulted in a lower peritonitis episode per patient per month ratio (from 1:36 to 1:122) in 2021, a lower death rate (from 19% to 6.6%) and lower incidences of shifts to hemodialysis (from 2%-9% to 0%) as compared to that before the implementation of the plan in 2019.

Conclusion: The implementation of the "peritonitis rescue plan" and the removal of the infected catheter within 3 days of peritonitis being detected was successful in improving the standard of care for patients undergoing CAPD.

引言:在接受持续性非卧床腹膜透析(CAPD)的患者中,超声有助于早期识别腹膜炎。方法:进行回顾性分析,以评估超声引导下移除Tenckhoff导管在减少CAPD患者转为血液透析或死亡等并发症方面的有效性。结果:“腹膜炎抢救计划”支持了及时做出移除受感染导管的决策,并导致2021年每位患者每月腹膜炎发作率较低(从1:36降至1:122),与2019年该计划实施前相比,死亡率较低(从19%降至6.6%),转为血液透析的发生率较低(由2%-9%降至0%) 检测到腹膜炎的天数成功地提高了接受CAPD的患者的护理标准。
{"title":"Rescue plan for CAPD peritonitis: Using ultrasonography as a guide on when to remove the catheter.","authors":"Dusit Lumlertgul,&nbsp;Nantawan Tinroongroj,&nbsp;Suthaporn Lumlertgul,&nbsp;Pannamart Siwapitak,&nbsp;Rattanaluck Tungkanakorn,&nbsp;Supaporn Kaewpanya","doi":"10.1111/1744-9987.14042","DOIUrl":"10.1111/1744-9987.14042","url":null,"abstract":"<p><strong>Introduction: </strong>Ultrasound has been found to facilitate early identification of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).</p><p><strong>Methods: </strong>A retrospective analysis was carried out to evaluate the effectiveness of ultrasonography-guided removal of the Tenckhoff catheter in reducing complications like a shift to hemodialysis or death in CAPD patients.</p><p><strong>Results: </strong>The \"peritonitis rescue plan\" supported timely decision-making for the removal of the infected catheter and resulted in a lower peritonitis episode per patient per month ratio (from 1:36 to 1:122) in 2021, a lower death rate (from 19% to 6.6%) and lower incidences of shifts to hemodialysis (from 2%-9% to 0%) as compared to that before the implementation of the plan in 2019.</p><p><strong>Conclusion: </strong>The implementation of the \"peritonitis rescue plan\" and the removal of the infected catheter within 3 days of peritonitis being detected was successful in improving the standard of care for patients undergoing CAPD.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10076298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current status of low-density lipoprotein apheresis treatment for patients with peripheral artery disease and chronic kidney disease in Japanese clinical database. 日本临床数据库中外周动脉疾病和慢性肾脏疾病患者单采低密度脂蛋白治疗的现状。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-16 DOI: 10.1111/1744-9987.14046
Yu Watanabe, Akihito Tanaka, Kazuhiro Furuhashi, Shoichi Maruyama

Introduction: Patients with peripheral arterial disease (PAD) have a poorer prognosis than those without PAD. PAD complications worsen the prognosis of patients with chronic kidney disease (CKD), especially those on maintenance dialysis. Although low-density lipoprotein apheresis (LDL-A) is expected to be effective in treating severe PAD, there are no large-scale reports on the prognosis of patients undergoing LDL-A.

Methods: We obtained a clinical database from April 2008 to August 2021 and selected 924 238 patients with CKD. We selected patients with disease codes of lower limb arteriosclerosis obliterans, arteriosclerosis obliterans, and critical limb ischemia or foot ulcer. Patients who were prescribed antithrombotic medications were included. Patients who used steroids were excluded. Among these patients, those undergoing blood purification considered LDL-A were selected, and their current status was investigated.

Results: We included 147 patients (113 males and 34 females). The mean patient age was 70 ± 10 years. Diabetes mellitus was present in 86%, ischemic heart disease in 34%, and stroke in 48%. Maintenance dialysis patients accounted for 86% of the patients. Statins were administered to 40% of the patients, and bypass surgery was performed in 2.7%. The median observation period was 812 days, and the mortality rate was 41%.

Conclusion: LDL-A was performed in a small population of patients with CKD with the most severe form of PAD. The prognosis for these patients is extremely poor. Therefore, strategies to improve prognosis are important.

引言:外周动脉疾病(PAD)患者的预后比没有PAD的患者差。PAD并发症恶化了慢性肾脏疾病(CKD)患者的预后,尤其是那些接受维持性透析的患者。尽管低密度脂蛋白单采(LDL-A)有望有效治疗严重PAD,但目前还没有关于接受LDL-A的患者预后的大规模报告。方法:我们获得了2008年4月至2021年8月的临床数据库,选择了924 238名CKD患者。我们选择了具有下肢动脉硬化闭塞症、动脉硬化闭塞性和严重肢体缺血或足部溃疡疾病代码的患者。服用抗血栓药物的患者也包括在内。使用类固醇的患者被排除在外。在这些患者中,选择了那些接受血液净化并考虑LDL-A的患者,并对他们的现状进行了调查。结果:我们纳入了147名患者(113名男性和34名女性)。患者平均年龄为70岁 ± 10 年。糖尿病占86%,缺血性心脏病占34%,中风占48%。维持性透析患者占86%。40%的患者服用他汀类药物,2.7%的患者进行了搭桥手术。中位观察期为812 天,死亡率为41%。结论:LDL-A在一小部分CKD患者中进行,其中PAD最为严重。这些患者的预后极差。因此,改善预后的策略很重要。
{"title":"Current status of low-density lipoprotein apheresis treatment for patients with peripheral artery disease and chronic kidney disease in Japanese clinical database.","authors":"Yu Watanabe,&nbsp;Akihito Tanaka,&nbsp;Kazuhiro Furuhashi,&nbsp;Shoichi Maruyama","doi":"10.1111/1744-9987.14046","DOIUrl":"10.1111/1744-9987.14046","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with peripheral arterial disease (PAD) have a poorer prognosis than those without PAD. PAD complications worsen the prognosis of patients with chronic kidney disease (CKD), especially those on maintenance dialysis. Although low-density lipoprotein apheresis (LDL-A) is expected to be effective in treating severe PAD, there are no large-scale reports on the prognosis of patients undergoing LDL-A.</p><p><strong>Methods: </strong>We obtained a clinical database from April 2008 to August 2021 and selected 924 238 patients with CKD. We selected patients with disease codes of lower limb arteriosclerosis obliterans, arteriosclerosis obliterans, and critical limb ischemia or foot ulcer. Patients who were prescribed antithrombotic medications were included. Patients who used steroids were excluded. Among these patients, those undergoing blood purification considered LDL-A were selected, and their current status was investigated.</p><p><strong>Results: </strong>We included 147 patients (113 males and 34 females). The mean patient age was 70 ± 10 years. Diabetes mellitus was present in 86%, ischemic heart disease in 34%, and stroke in 48%. Maintenance dialysis patients accounted for 86% of the patients. Statins were administered to 40% of the patients, and bypass surgery was performed in 2.7%. The median observation period was 812 days, and the mortality rate was 41%.</p><p><strong>Conclusion: </strong>LDL-A was performed in a small population of patients with CKD with the most severe form of PAD. The prognosis for these patients is extremely poor. Therefore, strategies to improve prognosis are important.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10367850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: A pilot study". 更正“每周特立帕肽对血清甲状旁腺激素相对较低的血液透析患者骨和矿物质代谢的影响:一项初步研究”。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-30 DOI: 10.1111/1744-9987.14044
{"title":"Correction to \"Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: A pilot study\".","authors":"","doi":"10.1111/1744-9987.14044","DOIUrl":"10.1111/1744-9987.14044","url":null,"abstract":"","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10495140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geriatric Depression Scale predicts mortality in elderly patients on chronic hemodialysis. 老年抑郁量表预测老年慢性血液透析患者的死亡率。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-07-12 DOI: 10.1111/1744-9987.14036
Maurizio Bossola, Gilda Pepe, Emanuela Antocicco, Camilla Illuminati, Enrico Di Stasio

Introduction: The aim of this study was to determine if the Geriatric Depression Scale (GDS) was predictor of mortality in elderly patients on chronic hemodialysis (HD).

Methods: A total of 140 HD patients ≥65 years were studied. Symptoms of depression were assessed through GDS and cognitive function through the Mini Mental State Examination (MMSE). GDS scores 0-9 are considered normal (Group 1); scores of 10-20 (Group 2) and 21-30 (Group 3) indicate mild and severe depression.

Results: Median GDS was 13 (11-15): 54 patients in Group 1, 49 in Group 2, and 37 in Group 3. After a follow-up of 58.85 ± 38.8 months, 94 patients died and 46 were alive. Kaplan-Meier survival was significantly lower in patients of Groups 2 and 3 than in Group 1 (log-rank χ2 : 101.9; DF: 2; p < 0.0001). According to Cox regression analysis, mortality was associated with age and GDS, and inversely associated with MMSE and Kt/V.

Conclusion: GDS predicts mortality in elderly HD patients.

引言:本研究的目的是确定老年抑郁量表(GDS)是否能预测慢性血液透析(HD)老年患者的死亡率 研究了几年。抑郁症状通过GDS评估,认知功能通过简易精神状态检查(MMSE)评估。GDS得分0-9被认为是正常的(第1组);10-20分(第2组)和21-30分(第3组)表示轻度和重度抑郁症。结果:GDS中位数为13(11-15):第1组54例,第2组49例,第3组37例。随访58.85 ± 38.8 数月后,94名患者死亡,46名患者存活。第2组和第3组患者的Kaplan-Meier生存率显著低于第1组(log秩χ2:101.9;DF:2;p 结论:GDS可预测老年HD患者的死亡率。
{"title":"Geriatric Depression Scale predicts mortality in elderly patients on chronic hemodialysis.","authors":"Maurizio Bossola,&nbsp;Gilda Pepe,&nbsp;Emanuela Antocicco,&nbsp;Camilla Illuminati,&nbsp;Enrico Di Stasio","doi":"10.1111/1744-9987.14036","DOIUrl":"10.1111/1744-9987.14036","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to determine if the Geriatric Depression Scale (GDS) was predictor of mortality in elderly patients on chronic hemodialysis (HD).</p><p><strong>Methods: </strong>A total of 140 HD patients ≥65 years were studied. Symptoms of depression were assessed through GDS and cognitive function through the Mini Mental State Examination (MMSE). GDS scores 0-9 are considered normal (Group 1); scores of 10-20 (Group 2) and 21-30 (Group 3) indicate mild and severe depression.</p><p><strong>Results: </strong>Median GDS was 13 (11-15): 54 patients in Group 1, 49 in Group 2, and 37 in Group 3. After a follow-up of 58.85 ± 38.8 months, 94 patients died and 46 were alive. Kaplan-Meier survival was significantly lower in patients of Groups 2 and 3 than in Group 1 (log-rank χ<sup>2</sup> : 101.9; DF: 2; p < 0.0001). According to Cox regression analysis, mortality was associated with age and GDS, and inversely associated with MMSE and Kt/V.</p><p><strong>Conclusion: </strong>GDS predicts mortality in elderly HD patients.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Double filtration plasmapheresis for bullous pemphigoid: Outcomes from the evaluation of eight patients. 双重过滤血浆置换治疗大疱性类天疱疮:8例患者的评价结果。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-15 DOI: 10.1111/1744-9987.14052
Hisao Kawahira, Kazuyasu Fujii, Yuko Higashi, Yasutoshi Yamada, Akihiko Mitsuke, Hideki Enokida, Takuro Kanekura
{"title":"Double filtration plasmapheresis for bullous pemphigoid: Outcomes from the evaluation of eight patients.","authors":"Hisao Kawahira, Kazuyasu Fujii, Yuko Higashi, Yasutoshi Yamada, Akihiko Mitsuke, Hideki Enokida, Takuro Kanekura","doi":"10.1111/1744-9987.14052","DOIUrl":"10.1111/1744-9987.14052","url":null,"abstract":"","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10009242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval. 低密度脂蛋白单采治疗因多种病因引起的难治性肾病综合征有益效果的最新证据已在全国和全球获得批准。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-18 DOI: 10.1111/1744-9987.14056
Eri Muso, Hiroko Kakita, Hiroyuki Suzuki, Tatsuo Tsukamoto

Low-density lipoprotein apheresis (LDL-A) therapy has shown reasonable efficacy in treating nephrotic syndrome (NS) refractory to initial drug therapy and has been covered by National Health Insurance for the indication of drug-resistant focal segmental glomerulosclerosis (FSGS) since 1992 in Japan and has contributed to liberating substantial number of patients of this disease from entering into end-stage renal disease by easier practical application in actual clinical settings. Subsequently, various beneficial evidence of this treatment has accumulated on those other than FSGS, however, due to the limitation of covered disease insurance only for FSGS, patients with diseases other than FSGS are unlikely to benefit from this treatment in practice. This review summarizes the therapeutic evidence of the beneficial effect of LDL-A accumulated to date and the mechanisms of action analyzed from multifaceted perspectives. examines the applicability of expanding insurance coverage for diseases other than FSGS.

低密度脂蛋白单采(LDL-A)疗法在治疗最初药物治疗难治的肾病综合征(NS)方面显示出合理的疗效,自1992年以来,日本已将其纳入国家健康保险的耐药局灶节段性肾小球硬化症(FSGS)指征范围,并有助于使大量肾病患者免于进入终末期肾脏疾病更容易在实际临床环境中实际应用。随后,在FSGS以外的患者身上积累了这种治疗的各种有益证据,然而,由于仅针对FSGS的承保疾病保险的限制,FSGS以外疾病的患者在实践中不太可能从这种治疗中受益。这篇综述总结了迄今为止积累的LDL-A有益作用的治疗证据,以及从多方面分析的作用机制。审查扩大FSGS以外疾病保险范围的适用性。
{"title":"Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval.","authors":"Eri Muso,&nbsp;Hiroko Kakita,&nbsp;Hiroyuki Suzuki,&nbsp;Tatsuo Tsukamoto","doi":"10.1111/1744-9987.14056","DOIUrl":"10.1111/1744-9987.14056","url":null,"abstract":"<p><p>Low-density lipoprotein apheresis (LDL-A) therapy has shown reasonable efficacy in treating nephrotic syndrome (NS) refractory to initial drug therapy and has been covered by National Health Insurance for the indication of drug-resistant focal segmental glomerulosclerosis (FSGS) since 1992 in Japan and has contributed to liberating substantial number of patients of this disease from entering into end-stage renal disease by easier practical application in actual clinical settings. Subsequently, various beneficial evidence of this treatment has accumulated on those other than FSGS, however, due to the limitation of covered disease insurance only for FSGS, patients with diseases other than FSGS are unlikely to benefit from this treatment in practice. This review summarizes the therapeutic evidence of the beneficial effect of LDL-A accumulated to date and the mechanisms of action analyzed from multifaceted perspectives. examines the applicability of expanding insurance coverage for diseases other than FSGS.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10012270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short term-efficacy and tolerability of Rheocarna, a novel direct hemoperfusion adsorptive column, for chronic limb-threatening ischemia in dialysis patients: A single-center case series. Rheocarna,一种新型直接血液灌流吸附柱,治疗透析患者慢性肢体威胁性缺血的短期疗效和耐受性:一个单中心病例系列。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-21 DOI: 10.1111/1744-9987.14049
Eri Imai, Shuzo Kaneko, Ainori Hoshimoto, Rina Hisada, Makiko Harano, Emi Anno, So Hagiwara, Shunsuke Ozaki, Hiroko Torii, Yusuke Tsukamoto

Introduction: With population aging and lifestyle changes, the number of patients with chronic limb-threatening ischemia (CLTI) is increasing, and refractory or recurrent lesions are more common, especially in chronic dialysis patients. In March 2021, a new type of adsorptive cellulose bead column immobilized with dextran sulfate and L-tryptophan for direct hemoperfusion (DHP) was approved by Japan's medical insurance system as a treatment for CLTI.

Methods: We retrospectively analyzed 17 cases of CLTI in dialysis patients treated with DHP using the novel column (Rheocarna) (DHP-R) at our hospital from May 2021 to October 2022. The short-term of efficacy of DHP-R was judged qualitatively by the foot care team every 2 weeks based on the assessment of skin color, warmth, ulcer epithelialization or shrinkage of the ulcer area, and foot pain. The final judgment of efficacy was made after the final DHP-R session.

Results: The median age of patients was 66 years, the median dialysis duration was 10 years, 15 cases (88%) were male, and 15 cases (88%) had diabetes. The median total number of sessions was eight. In comparing the groups in which DHP-R was effective and ineffective, there was no significant difference in any factors including patient background data (i.e., age, diabetes, low-density lipoprotein cholesterol, hemoglobin, dialysis duration, etc.), type of anticoagulants, and presence of episodes of blood pressure drop or circuit clotting during session. Three cases with symptomatic hypotension during the session and two cases with circuit clotting that did not improve with increased heparin dose all resolved immediately after changing the anticoagulant from heparin to nafamostat mesylate (NM).

Conclusion: Identification of patients' characteristics in which DHP-R is favorable and some reliable index that allow a rapid decision to continue DHP-R are needed. In addition, validating whether the use of NM as anticoagulant affects the efficacy of DHP-R for CTLI treatment remains a challenge to resolve.

引言:随着人口老龄化和生活方式的改变,慢性肢体威胁性缺血(CLTI)患者数量不断增加,难治性或复发性病变更为常见,尤其是在慢性透析患者中。2021年3月,一种新型的用葡聚糖硫酸酯和L-色氨酸固定的吸附性纤维素珠柱被日本医疗保险系统批准作为CLTI的治疗方法,用于直接血液灌流(DHP)。方法:我们回顾性分析了2021年5月至2022年10月在我院使用新型柱(Rheocarna)(DHP-R)接受DHP治疗的透析患者中的17例CLTI。足部护理团队每2个月对DHP-R的短期疗效进行定性判断 周,根据皮肤颜色、温度、溃疡上皮化或溃疡面积缩小以及足部疼痛的评估。疗效的最终判断是在最后一次DHP-R治疗后做出的。结果:患者的中位年龄为66岁 年,中位透析时间为10 年,男性15例(88%),糖尿病15例(88%)。会话总数的中位数为8次。在比较DHP-R有效和无效的组时,包括患者背景数据(即年龄、糖尿病、低密度脂蛋白胆固醇、血红蛋白、透析持续时间等)、抗凝血剂类型以及治疗期间是否出现血压下降或回路凝血在内的任何因素均无显著差异。三例在治疗期间出现症状性低血压的病例和两例在增加肝素剂量后没有改善的回路凝血病例,在将抗凝剂从肝素改为甲磺酸那法莫司他(NM)后立即缓解。结论:需要确定DHP-R有利的患者特征和一些可靠的指标,以便快速决定是否继续DHP-R。此外,验证NM作为抗凝剂的使用是否会影响DHP-R治疗CTLI的疗效仍然是一个有待解决的挑战。
{"title":"Short term-efficacy and tolerability of Rheocarna, a novel direct hemoperfusion adsorptive column, for chronic limb-threatening ischemia in dialysis patients: A single-center case series.","authors":"Eri Imai,&nbsp;Shuzo Kaneko,&nbsp;Ainori Hoshimoto,&nbsp;Rina Hisada,&nbsp;Makiko Harano,&nbsp;Emi Anno,&nbsp;So Hagiwara,&nbsp;Shunsuke Ozaki,&nbsp;Hiroko Torii,&nbsp;Yusuke Tsukamoto","doi":"10.1111/1744-9987.14049","DOIUrl":"10.1111/1744-9987.14049","url":null,"abstract":"<p><strong>Introduction: </strong>With population aging and lifestyle changes, the number of patients with chronic limb-threatening ischemia (CLTI) is increasing, and refractory or recurrent lesions are more common, especially in chronic dialysis patients. In March 2021, a new type of adsorptive cellulose bead column immobilized with dextran sulfate and L-tryptophan for direct hemoperfusion (DHP) was approved by Japan's medical insurance system as a treatment for CLTI.</p><p><strong>Methods: </strong>We retrospectively analyzed 17 cases of CLTI in dialysis patients treated with DHP using the novel column (Rheocarna) (DHP-R) at our hospital from May 2021 to October 2022. The short-term of efficacy of DHP-R was judged qualitatively by the foot care team every 2 weeks based on the assessment of skin color, warmth, ulcer epithelialization or shrinkage of the ulcer area, and foot pain. The final judgment of efficacy was made after the final DHP-R session.</p><p><strong>Results: </strong>The median age of patients was 66 years, the median dialysis duration was 10 years, 15 cases (88%) were male, and 15 cases (88%) had diabetes. The median total number of sessions was eight. In comparing the groups in which DHP-R was effective and ineffective, there was no significant difference in any factors including patient background data (i.e., age, diabetes, low-density lipoprotein cholesterol, hemoglobin, dialysis duration, etc.), type of anticoagulants, and presence of episodes of blood pressure drop or circuit clotting during session. Three cases with symptomatic hypotension during the session and two cases with circuit clotting that did not improve with increased heparin dose all resolved immediately after changing the anticoagulant from heparin to nafamostat mesylate (NM).</p><p><strong>Conclusion: </strong>Identification of patients' characteristics in which DHP-R is favorable and some reliable index that allow a rapid decision to continue DHP-R are needed. In addition, validating whether the use of NM as anticoagulant affects the efficacy of DHP-R for CTLI treatment remains a challenge to resolve.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10030051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Apheresis and Dialysis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1